Prelude Executives Unite in 1.5 Million‑Share Option Surge Amid JAK2 Breakthrough—Market Tuning Up?
Executive buying at Prelude Therapeutics signals confidence in its JAK2 inhibitor pipeline, yet investors should stay cautious amid current volatility.
3 minutes to read